FDA Provides Consumer Advice Following Recall of Products for Infants and Children

SILVER SPRING, Md., May 1 /PRNewswire-USNewswire/ -- Working in consultation with the United States Food and Drug Administration (FDA), McNeil Consumer Healthcare is implementing a voluntary recall of infant and children's liquid products due to manufacturing deficiencies which may affect quality, purity or potency. Following McNeil's recall announcement on Friday evening, the FDA is providing additional advice to consumers.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO )

"We want to be certain that consumers discontinue using these products and that they know what to do if they have concerns about a specific product," said Commissioner of Food and Drugs Margaret A. Hamburg, M.D.

"While the potential for serious health problems is remote, Americans deserve medications that are safe, effective and of the highest quality. We are investigating the products and facilities associated with this recall and will provide updates as we learn more."

What products are affected by this recall?

The products include certain liquid infant's and children's Tylenol®, Motrin®, Zyrtec®, and Benadryl® products. For a complete list of recalled products, please see the recall notice:

http://www.mcneilproductrecall.com/page.jhtml?id=/include/new_recall.inc
Why were these products recalled?

McNeil Consumer Healthcare is initiating this voluntary recall because some of these products may not meet required quality standards. As a precautionary measure, parents and caregivers should not administer these products to their children. Some of the products included in the recall may contain a higher concentration of active ingredient than specified; others contain inactive ingredients that may not meet internal testing requirements; and others may contain tiny particles. While the potential for serious medical events is remote, FDA advises consumers who have purchased these recalled products to discontinue use.

What can I use instead of the recalled products?

There are a number of other products on the market, including generic versions of the recalled products, which are intended for use in infants and children and are not affected by the recall. FDA recommends that you check the labeling of these products. If you have any questions, you should discuss this with your pharmacist or other health care professional. FDA does not anticipate that there will be a shortage of alternative products.

Can I give my child adult strength Tylenol® or Motrin® products that are not being recalled?

No. Consumers should not give drug products to infants and children that are not intended for those age groups. This could result in serious harm.

What should I do if I have some of the medication at home?
FDA recommends that consumers stop using these products.
For further instructions, see McNeil's website at:
http://www.mcneilproductrecall.com/
I gave my child some of the medication. What do I do? Is my child at risk?

According to the information the FDA has received at this time, the potential for serious medical problems is remote. If your child exhibits any unexpected symptoms after use of any of the recalled products, contact your health care professional.

If I think my child may be having an adverse reaction to one of the products involved in this recall, who should I notify?

Adverse reactions or quality problems experienced with the use of these products may be reported to FDA's MedWatch Adverse Event Reporting program either online, by regular mail, or by fax, using the contact information at the bottom of this sheet. The agency asks health care professionals and consumers to report any adverse reactions to the FDA's MedWatch Program by fax at 1-800-FDA-0178, by mail at MedWatch, FDA, 5600 Fishers Lane, Rockville, MD 20852-9787, or on the MedWatch website at http://www.fda.gov/medwatch.

Related information
Facts about Current Good Manufacturing Practices (CGMPs)

HUNT VALLEY, Md., April 30 /PRNewswire/ -- Multi-platinum singer-songwriter Taylor Swift can now add COVERGIRL to her list of accomplishments. The 20-year-old, GRAMMY award-winning star has just finished shooting her first advertisements for the beauty giant, and will represent a new line of luxury products for the brand. The ads are scheduled to debut in January 2011.

To view the multimedia assets associated with this release, please click: http://multivu.prnewswire.com/mnr/covergirl/43861/

(Photo: http://www.newscom.com/cgi-bin/prnh/20100430/MM96825 )

With millions of fans worldwide, Swift has achieved remarkable success since first entering the country music scene in 2006. To date she has sold more than thirteen million albums and is the top-selling digital artist in music history. Her second album, Fearless, has spent more weeks in the top spot on Billboard's all-genre Top 20 chart than any other album this decade. The GRAMMY Awards, the Country Music Association, the Academy of Country Music, and the American Music Awards all named Fearless the 2009 Country Album of the Year and, this year, the album won the all-genre GRAMMY Award for Album of the year. Last year, Swift earned the American Music Award for Artist of the Year and was the youngest artist ever to win the prestigious CMA Award for Entertainer of the Year.

"With her fresh beauty and authentic style, Taylor is a wonderful addition to the COVERGIRL family," said Vince Hudson, General Manager, COVERGIRL Cosmetics. "Through all her success, Taylor remains a grounded and sincere woman who connects with fans everywhere just by being true to who she is. She personifies the iconic image of the brand while representing the next generation of both inner and outer beauty."

"I am so excited to become the next COVERGIRL," said Swift. "I have admired many of the COVERGIRLs since I was a little girl . . . great artists and actresses who are confident and still themselves. It's like a dream come true to be a part of the future of COVERGIRL."

Since its introduction in 1961, the COVERGIRL brand has been a pioneer in celebrating women's inner and outer beauty, and their drive to look and be their best selves. The long list of famous COVERGIRLs has included Christie Brinkley, Cheryl Tiegs, Rachel Hunter, Tyra Banks, Niki Taylor and Molly Sims, and its current roster of COVERGIRLs includes the dynamic Queen Latifah, Ellen DeGeneres, Rihanna, and Drew Barrymore.

Visit http://www.covergirl.com/ for more information on COVERGIRL's family of spokeswomen and its extensive lineup of products for women of all ages.

About P&G Beauty & Grooming

P&G Beauty & Grooming products help make beauty dreams real for women worldwide and help men look, feel and be their best everyday. With more than 100 brands available in nearly 130 countries, P&G's beauty and grooming products delivered sales of nearly $28 billion in fiscal year 2007/08 , making it one of the world's largest beauty and grooming companies. P&G Beauty & Grooming offers trusted brands with leading technology to meet the full complement of beauty and grooming needs, including Pantene®, Olay®, Head & Shoulders®, Max Factor®, Cover Girl®, DDF®, Frederic Fekkai®, Wellaflex®, Rejoice®, Sebastian Professional®, Herbal Essences®, Koleston®, Clairol Professional®, Nice 'n Easy®, Venus®, Gillette®, SK-II®, Wella Professionals®, Braun® and a leading Prestige Fragrance division that spans from point of market entry consumers to high end luxury with global brands such as Hugo Boss®, Lacoste®, and Christina Aguilera®. Please visit http://www.pg.com for the latest news and in-depth information about P&G and its brands.

WILMINGTON, Del., April 30 /PRNewswire-FirstCall/ -- AstraZeneca and POZEN Inc. today announced the U.S. Food and Drug Administration (FDA) has approved VIMOVO(TM) (naproxen and esomeprazole magnesium) delayed-release tablets for the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers.(1) VIMOVO, co-developed by POZEN Inc. and AstraZeneca, is a fixed-dose combination of enteric-coated naproxen, a pain-relieving non-steroidal anti-inflammatory drug (NSAID), and immediate-release esomeprazole, a proton pump inhibitor (PPI). The FDA approval was supported by data from a clinical development program, including results from the pivotal PN400-301 and PN400-302 studies, which showed patients taking VIMOVO experienced significantly fewer endoscopic gastric ulcers, compared to patients receiving enteric-coated naproxen.(2)

(Logo: http://www.newscom.com/cgi-bin/prnh/20091027/PH99766LOGO )

Twenty-seven million Americans are affected by osteoarthritis(3), which is the most common form of arthritis.(4) While many patients with osteoarthritis treat their symptoms with NSAIDs(5), 50% of chronic NSAID users are at risk of gastrointestinal ulcers.(5)

"In a single pill, VIMOVO provides a proven pain reliever with a built-in PPI for arthritis patients at-risk for NSAID-associated gastric ulcers," said Howard Hutchinson, M.D., Chief Medical Officer, AstraZeneca. "The approval also demonstrates the commitment of AstraZeneca and POZEN to provide a new pain relief option that addresses the unmet medical needs of these patients."

In the PN400-301 and 302 studies, the primary end point was the cumulative incidence of gastric ulcers through six months. In each of the trials, patients received either VIMOVO or enteric-coated naproxen 500 mg, twice daily, over a six-month treatment period. Endoscopies were performed at baseline and at one, three, and six months. Data from study PN400-301 showed a 4.1% incidence of gastric ulcers in patients taking VIMOVO, compared to 23.1% among patients taking enteric-coated naproxen (p<0.001). Study PN400-302 showed a 7.1% incidence of gastric ulcers among patients taking VIMOVO, compared to 24.3% with enteric-coated naproxen (p<0.001).(2)

The most commonly observed adverse events in the clinical trials (experienced by >5% of patients in the VIMOVO group) were erosive gastritis, dyspepsia, gastritis, diarrhea, gastric ulcer, upper abdominal pain and nausea.(1)

Important Safety Information about VIMOVO
Cardiovascular Risk
-- Naproxen, a component of VIMOVO, may cause an increased risk of
serious cardiovascular thrombotic events, myocardial infarction, and
stroke, which can be fatal. This risk may increase with duration of
use. Patients with cardiovascular disease or risk factors for
cardiovascular disease may be at greater risk.
-- VIMOVO is contraindicated for the treatment of peri-operative pain in
the setting of coronary artery bypass graft (CABG) surgery.
Gastrointestinal Risk
-- NSAIDs, including naproxen, a component of VIMOVO, cause an increased
risk of serious gastrointestinal adverse events including bleeding,
ulceration, and perforation of the stomach or intestines, which can be
fatal. These events can occur at any time during use and without
warning symptoms. Elderly patients are at greater risk for serious
gastrointestinal (GI) events.

VIMOVO is contraindicated in patients with known hypersensitivity to any component of VIMOVO or substituted benzimidazoles; in patients with a history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs; in patients during the peri-operative period in the setting of coronary artery bypass graft (CABG) surgery; or in patients in the late stages of pregnancy.

Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals.

Treatment should be withdrawn when active and clinically significant bleeding from any source occurs.

As with all NSAIDs, VIMOVO can lead to the onset of new hypertension or worsening of pre-existing hypertension, either of which may contribute to the increased incidence of CV events. Blood pressure should be monitored closely.

Fluid retention and edema have been observed in some patients taking NSAIDs, including VIMOVO. NSAIDs should be used with caution in patients with fluid retention or heart failure.

NSAIDs, including VIMOVO, may diminish the antihypertensive effect of angiotensin converting enzyme (ACE) inhibitors and angiotensin II antagonists, beta-blockers, and in some patients can reduce the natriuretic effect of furosemide and thiazides.

VIMOVO can be administered with low-dose aspirin (less than or equal to 325 mg/day) therapy. The concurrent use of aspirin and VIMOVO may increase the risk of serious adverse events.

VIMOVO is not recommended in patients with moderate or severe renal insufficiency. In addition, NSAIDs may cause renal toxicity.

Serious skin adverse reactions such as exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis, which can be fatal and can occur without warning. Discontinue VIMOVO at first appearance of skin rash or any other sign of hypersensitivity.

Symptomatic response to esomeprazole, a component of VIMOVO, does not preclude the presence of gastric malignancy.

Atrophic gastritis has been noted occasionally in gastric corpus biopsies from patients treated long-term with omeprazole, of which VIMOVO contains an enantiomer.

Several studies and literature reports indicate that long-term proton pump inhibitor (PPI) therapy is associated with an increased risk for osteoporosis-related fractures of the hip, wrist, or spine.

Esomeprazole, a component of VIMOVO, inhibits gastric acid secretion and may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, ketoconazole, iron salts, and digoxin).

Concomitant use of VIMOVO and warfarin may result in increased risk of bleeding complications. Monitor for increases in INR and prothrombin time.

Please see Important Safety Information and Prescribing Information for VIMOVO, including Boxed Warnings.

NOTES TO EDITORS
About VIMOVO

VIMOVO is a fixed-dose combination of delayed-release enteric-coated naproxen, a non-steroidal anti-inflammatory drug (NSAID), and immediate-release esomeprazole, a stomach acid-reducing proton pump inhibitor (PPI), approved for the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis and to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers. VIMOVO is not recommended for use in children younger than 18 years of age.(1)

VIMOVO has been developed as a sequential-delivery tablet formulation combining an immediate-release esomeprazole magnesium layer and an enteric-coated naproxen core. As a result, esomeprazole is released first in the stomach, prior to the dissolution of naproxen in the small intestine. The enteric coating prevents naproxen release at pH levels below 5.5 providing protection against possible local gastric toxicity of naproxen.

AstraZeneca submitted a Marketing Authorization Application (MAA) to the European Medicines Association (EMEA) for VIMOVO on October 15, 2009.

Upon the FDA's notification of approval of the New Drug Application for VIMOVO, a $20 million milestone payment from AstraZeneca will be payable to POZEN.

About Osteoarthritis

Osteoarthritis is a degenerative joint disease caused by the breakdown and eventual loss of the cartilage of one or more joints.(4) Osteoarthritis is the most common form of arthritis and the most common cause of chronic pain(4), affecting 151 million individuals worldwide(6) and 27 million Americans.(3) A combination of factors can contribute to osteoarthritis, including being overweight, aging, joint injury or stress, heredity, and muscle weakness.(7) Osteoarthritis commonly affects the hands, spine or large weight-bearing joints, such as the hips and knees.(7)

About Rheumatoid Arthritis

Rheumatoid arthritis is a chronic disease, mainly characterized by inflammation of the lining, or synovium, of the joints. It can lead to long-term joint damage, resulting in chronic pain, loss of function and disability.(8)

About Ankylosing Spondylitis

Ankylosing spondylitis is a chronic inflammatory disease that primarily causes pain and inflammation of the joints between the vertebrae of the spine and the joints between the spine and pelvis (sacroiliac joints). Ankylosing spondylitis may also cause inflammation and pain in other parts of the body as well.(9)

ABOUT POZEN

POZEN Inc., headquartered in Chapel Hill, NC, is a pharmaceutical company committed to transforming medicine that transforms lives. Since its founding in 1996, POZEN has successfully created novel pharmacologic agents primarily for pain and pain-related conditions by combining existing drug therapies that result in superior patient outcomes. Moving forward, POZEN is poised to become a model 21st century pharmaceutical company dedicated to ensuring that they produce cost-effective, evidence-based medicines; take a fresh approach to sales, marketing and medical education; and deliver high-quality, affordable pharmaceuticals to their customers. The Company's common stock is traded on The NASDAQ Stock Market under the symbol "POZN." For more detailed company information, including copies of this and other press releases, please visit: http://www.pozen.com/.

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialization of prescription medicines. As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease medicines, AstraZeneca generated global revenues of $32.8 billion in 2009. In the United States, AstraZeneca is a $14.8 billion health care business.

For more information about AstraZeneca in the US or our AZ&Me(TM) Prescription Savings programs, please visit: http://www.astrazeneca-us.com/ or call 1-800-AZandMe (292-6363).

Capitol Bancorp Completes Divestiture of Napa Community BankRabobank to continue model of service and community involvement in Napa Valley

LANSING, Mich., and ROSEVILLE, Calif., April 30 /PRNewswire-FirstCall/ -- Capitol Bancorp Limited and Rabobank, N.A. today jointly announced that they have completed the sale of Capitol's California-based affiliate, Napa Community Bank, to Rabobank, N.A., a community bank with over 100 California locations.

"We welcome Napa Community Bank customers and employees to the Rabobank family," said Ronald Blok, CEO of Rabobank, N.A. "We are excited about the opportunity to serve customers here with new products and services and the resources that come with Rabobank."

Capitol's Chairman and CEO Joseph D. Reid said, "We are pleased with the progress of our widely publicized divestiture program. This sale is the third transaction to be completed within a week, enabling Capitol Bancorp to efficiently reallocate more than $30 million of equity capital that can now be redeployed to those affiliates that continue to face economic challenges."

About Capitol Bancorp Limited

Capitol Bancorp Limited is a $5.1 billion national community banking company with a network of separately chartered banks in 16 states. Founded in 1988, Capitol Bancorp Limited has executive offices in Lansing, Michigan, and Phoenix, Arizona.

About Rabobank, N.A.

Rabobank, N.A. is a California community bank that provides personalized service and a full array of quality products to individuals, businesses, organizations and agricultural clients. With 93 retail branches and 15 financial service centers, we serve the needs of communities from Sacramento to the Imperial Valley through local decision making and active community involvement by our employees. http://www.rabobankamerica.com/

SHANGHAI, April 30 /PRNewswire-FirstCall/ -- Shanghai Expo - As a leading provider of TD-LTE technology, the Networks business of Motorola, Inc. announced today that it is demonstrating end-to-end TD-LTE experiences at the Information and Communication Pavilion to support China Mobile Communications Corporation's (CMCC) presence at the Shanghai Expo.

Motorola's demonstration highlights include:
-- Simultaneous video streams: A single TD-LTE USB dongle can stream 24
simultaneous video streams while supporting very high-speed Internet
browsing applications, at a total data rate of 20Mbps, demonstrating
the true broadband performance of TD-LTE. A TD-LTE carrier in 20MHz
can support transmission of a few hundred video streams
simultaneously. In the near future, TD-LTE subscribers will then be
able to access a collection of high-bandwidth and low-latency Internet
applications including mobile TV, on-demand videos and video blogging
anywhere.
-- TD-LTE demonstration vehicle: A two-wheeled, self-balancing electric
vehicle carrying a camera and a laptop showcases real-time TD-LTE
performance on the move. Live video captured by the moving camera can
be viewed on other laptops and the main screen within the
demonstration area via a TD-LTE USB dongle. In addition, visitors will
be able to set up a video stream session between the laptop on the
vehicle and the laptops within the demonstration area. In the near
future, TD-LTE subscribers will be able to receive and transmit data,
access favorite content, collaborate or conduct business at a speed
about 20 times faster than the current 3G network, as they move on
high-speed railways at speeds of about 350km per hour.

"Motorola and China Mobile share the same commitment to accelerating TD-LTE commercialization and globalization," said Dr. Mohammad Akhtar, corporate vice president and general manager, Motorola Networks business in Asia Pacific. "We are very excited to support China Mobile in bringing the TD-LTE experience to Shanghai Expo. TD-LTE is now a commercial reality, making LTE a truly encompassing global technology standard."

These demonstrations showcase Motorola's third-generation OFDM-based products and a set of core networks running the latest specifications software and related application servers. Motorola's TD-LTE devices will receive and transmit over-the-air (OTA) data including high-definition video from and to the application servers, high-speed data from and to the application servers as well as from and to the Internet.

Motorola provides indoor TD-LTE network coverage for major pavilions at the Shanghai Expo including the Expo Center and the U.S. Pavilion as well as backup systems to other vendor solutions in other pavilions. To help operators build a healthy TD-LTE ecosystem, Motorola will also integrate and launch the TD-LTE USB dongle that supports 2.3GHz at the event.

Motorola is one of the few vendors in the industry that has expertise in, has committed to and is investing in FDD LTE and TD-LTE, as well as WiMAX. This leadership position builds on Motorola's more than 10 years of OFDM expertise and world-class R&D facilities devoted to TD-LTE development, including two R&D centers in China. Motorola's Wireless Broadband Access Solutions (WBAS) Hangzhou Center and the Wideband Base Transceiver System (WBTS) China Center have been working with Chinese operators for many years and can provide valuable insights that enable a prompt response to local needs.

Interest in TD-LTE continues to grow due to several key factors:
-- The tremendous growth of data use while mobile falling prices, more
variety and improved ease of use in end user devices
-- Additional spectrum is necessary for serving more users
-- TDD spectrum traditionally auctioned for lower cost/radio
frequency/population
-- Global and local roaming between FDD and TDD networks, allowing both
networks to be used in the same geographic area

Dr. Akhtar added, "We see the growing interest in TD-LTE as the technology delivers increased capacity and a lower cost per bit. Motorola is the leader in TD-LTE through trials and engagements with various operators around the world. The selection by China Mobile today once again demonstrates the reliability and maturity of our TD-LTE solution."

Motorola's TD-LTE Expertise and Achievements

Motorola has gained significant experience and momentum in TD-LTE thanks to its OFDM experience, which was instrumental in the development and design of the TD-LTE 4Tx/8Rx solution. These engineering innovations resulted in one of the most efficient radios in the market - allowing it to be compact enough to be installed and mounted on a tower. With more performance packed into a smaller unit, operators can get better performance out of the sites they deploy and may be able to use fewer sites, thereby lowering their total cost of ownership in less densely populated areas.

Motorola's ongoing advancements in TD-LTE include its recently announced company-wide initiatives for the U.S. Pavilion at Shanghai Expo, end-to-end TD-LTE demonstration via the world's first TD-LTE USB dongle and first OTA TD-LTE data session on a TD-LTE network in Shanghai. These achievements, plus being the first vendor that completed all radio frequency (RF) test cases in CMCC's TD-LTE trial including the ability to support the TD-LTE maximum data rate in 20MHz and successfully running multiple user devices, and conducting the world's first TD-LTE live drive demo at ITU Telecom 2009 in Geneva, are further demonstrations of Motorola's LTE expertise.

Motorola's Networks business delivers fully integrated and customizable media solutions enabling operators to offer personalized, rich media experiences to their subscribers. As a global wireless infrastructure leader, Motorola is committed to 4G with WiMAX and LTE solutions that provide a way for operators to profitably meet the ever-growing demand for mobile broadband today while giving 2G and 3G customers a future path as we continue to support their legacy networks. Motorola brings its services, fourth-generation OFDM platform and 25 years of wireless data systems innovation, experience and expertise to bear as operators - wireline, wireless, cable and telco - seek to evolve their networks for the future.

Motorola is known around the world for innovation in communications and is focused on advancing the way the world connects. From broadband communications infrastructure, enterprise mobility and public safety solutions to high-definition video and mobile devices, Motorola is leading the next wave of innovations that enable people, enterprises and governments to be more connected and more mobile. Motorola had sales of US$22 billion in 2009. For more information, please visit http://www.motorola.com/.

Motorola Announces Successful Completion of Phase I TD-LTE Field Trials With China's MIITPositive results fully support the ongoing field trials on a larger scale, demonstrating TD-LTE commercial readiness with a new milestone

SHANGHAI, April 30 /PRNewswire-FirstCall/ -- Shanghai Expo -- The Networks business of Motorola, Inc. announced today that it has successfully completed the Phase I TD-LTE field trials with China's Ministry of Industry and Information Technology (MIIT). This over-the-air (OTA) TD-LTE trial included key functionality, performance and mobility test cases in a multi-sector, multi-site environment that lays a solid foundation for large scale TD-LTE deployment.

Motorola is now ready to begin Phase II TD-LTE field trials with increased focus on applications and quality of service (QoS) in Shunyi, Beijing.

The milestone follows the recently announced TD-LTE key functionalities test initiated by the TD-LTE working group, which was set up by MIIT in June 2009 with China's three telecom operators and other key industry partners. Motorola's unmatched expertise in OFDM mobile broadband technologies and class-leading TD-LTE solution performance has been leveraged as part of these efforts to develop a globally competitive TD-LTE end-to-end solution and drive for a healthy TD-LTE ecosystem. Motorola also leveraged its world-class research and development (R&D) facilities devoted to the development of TD-LTE, including two R&D centers in China - the Wireless Broadband Access Solutions (WBAS) Hangzhou Center and the Wideband Base Transceiver System (WBTS) China Center - to enable a prompt response to local customer requirements.

"Thanks to our valued collaboration with partners, TD-LTE is well on its way to realizing its potential as a promising next-generation wireless technology that enables a compelling media mobility lifestyle," said Dr. Mohammad Akhtar, corporate vice president and general manager, Motorola Networks business in Asia Pacific. "We are very pleased to have reached yet another milestone with the successful completion of Phase I TD-LTE field trials and are looking forward to upcoming trial results. The announcement today is a testament to Motorola's commitment to TDD spectrum operators around the world and once again demonstrates the maturity of our TD-LTE solution."

As an important TD-LTE partner of China Mobile Communications Corporation for the TD-LTE showcase network at Shanghai Expo, Motorola provides indoor network coverage for major pavilions. To help operators build a healthy TD-LTE ecosystem, Motorola will also work with partners to integrate and launch TD-LTE USB dongles that support 2.3GHz at the event.

Dr. Akhtar added, "Accurate network simulation and planning, as well as highly efficient system optimization are key factors for successful deployment of a LTE network. Motorola has an advanced simulation platform based on LTE and is now working closely with China Mobile to leverage the proven TD-LTE platform at Shanghai Expo and in Beijing Shunyi. With its more than 10 years of OFDM expertise and award-winning LTE solutions, Motorola will be in the best position to enable TDD spectrum operators to roll out their next-generation networks."

Interest in TD-LTE continues to grow because of several key factors: the low cost of TDD spectrum that is particularly attractive to emerging and developing markets; operators' continuing need for more capacity and spectrum; and the ability to roaming and hand-off between TD-LTE and FDD LTE networks. In effect, this ability to roam between FDD LTE and TD-LTE means operators can use TD-LTE networks to augment their FDD LTE network for more capacity or other applications such as video broadcasting, while operators choosing to use TD-LTE as their "main" network can still offer their subscribers the ability to roam to other operators' FDD LTE networks in different countries.

Motorola is one of the few vendors in the industry that has expertise in, and is committed to investing in multiple wireless broadband technologies, both FDD LTE and TD-LTE as well as WiMAX. In addition to the TD-LTE trials with MIIT, Motorola is actively engaged with global tier-one operators on TD-LTE trials.

Motorola's Networks business delivers fully integrated and customizable media solutions enabling operators to offer personalized, rich media experiences to their subscribers. As a global wireless infrastructure leader, Motorola is committed to 4G with WiMAX and LTE solutions that provide a way for operators to profitably meet the ever-growing demand for mobile broadband today while giving 2G and 3G customers a future path as we continue to support their legacy networks. Motorola brings its services, fourth-generation OFDM platform and 25 years of wireless data systems innovation, experience and expertise to bear as operators - wireline, wireless, cable and telco - seek to evolve their networks for the future.

Motorola is known around the world for innovation in communications and is focused on advancing the way the world connects. From broadband communications infrastructure, enterprise mobility and public safety solutions to high-definition video and mobile devices, Motorola is leading the next wave of innovations that enable people, enterprises and governments to be more connected and more mobile. Motorola had sales of US$22 billion in 2009. For more information, please visit http://www.motorola.com/.

HOUSTON, April 30 /PRNewswire/ -- Attorneys with The Lanier Law Firm are announcing a class action lawsuit filed today on behalf of Louisiana residents affected by the oil spill caused by the Deepwater Horizon explosion.

On April 20, 2010, an explosion and fire occurred on the Deepwater Horizon, a massive oil rig owned by Swiss-based Transocean Ltd. and leased to UK-based BP PLC .

According to the lawsuit, BP PLC, Transocean Ltd., Cameron International Corporation and Halliburton Energy Services violated the Oil Pollution Act and were negligent in failing to properly operate, inspect, and maintain the Deepwater Horizon rig. Attorneys for the plaintiffs also allege that the defendants' inadequately responded to the explosion and resulting oil leak, causing severe damage to the fragile ecosystem in the Gulf of Mexico.

The companies initially reported that the well was leaking 1,000 barrels per day, but evidence now shows that the well is leaking more than 5,000 barrels.

According to the lawsuit, the defendants "impaired the response to the emergency, greatly increasing the danger to the environment, human health, and the Gulf Coast economy, by knowingly understating the amount of oil that was leaking from the well." The lawsuit also alleges that the oil spill "has formed a vast expanse of thick, poisonous sludge, contaminating an area larger than the state of Rhode Island. The oil slick will continue to expand until the ruptured pipe is shut off, a process that could take weeks or months."

"By consciously understating the magnitude of the leak, the defendants put the entire Gulf Coast region in increasing danger," says attorney Mark Lanier. "This oil will not simply evaporate off the water, and in two months we're likely to be looking at a spill surpassing the Exxon Valdez disaster."

The lawsuit, Nova Affiliated, S.A. v. BP, PLC et al., No. 2:10-cv-01313, was filed April 30, 2010, in the U.S. District Court for the Eastern District of Louisiana. In addition to Mr. Lanier, the plaintiffs are represented by Dana Taschner with The Lanier Law Firm, as well as attorneys with New Orleans' Herman Herman Katz & Cotlar.

For more information, contact Alan Bentrup at 713-553-3358, alan@androvett.com or J.D. Cargill at 832-606-8335.

The Lanier Law Firm

CONTACT: Alan Bentrup, +1-713-553-3358, alan@androvett.com, or J.D.Cargill, +1-832-606-8335, both for The Lanier Law Firm